These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9380259)

  • 1. [Current views on the mechanisms of dopaminergic neuron death of the nigrostriatal system in Parkinson's disease].
    Bertrand E; Lechowicz W; Szpak GM; Dymecki J
    Neurol Neurochir Pol; 1997; 31(2):295-302. PubMed ID: 9380259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron metabolism and Parkinson's disease.
    Hirsch EC; Faucheux BA
    Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative mechanisms in nigral cell death in Parkinson's disease.
    Jenner P
    Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oxidative stress and the brain].
    Tanaka M
    Nihon Ronen Igakkai Zasshi; 1997 Sep; 34(9):706-10. PubMed ID: 9430979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does oxidative stress participate in nerve cell death in Parkinson's disease?
    Hirsch EC
    Eur Neurol; 1993; 33 Suppl 1():52-9. PubMed ID: 8375433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?
    Hirsch EC
    Ann Neurol; 1992; 32 Suppl():S88-93. PubMed ID: 1510386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
    Jenner P
    Acta Neurol Scand Suppl; 1993; 146():6-13. PubMed ID: 8333254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New face of neuromelanin.
    Double KL; Halliday GM
    J Neural Transm Suppl; 2006; (70):119-23. PubMed ID: 17017518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of neuronal loss in Parkinson's disease: a neuroanatomical-biochemical perspective.
    Hornykiewicz O
    Clin Neurol Neurosurg; 1992; 94 Suppl():S9-11. PubMed ID: 1320533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
    Enochs WS; Sarna T; Zecca L; Riley PA; Swartz HM
    J Neural Transm Park Dis Dement Sect; 1994; 7(2):83-100. PubMed ID: 7710667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
    Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
    Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immobilization stress causes increases in tetrahydrobiopterin, dopamine, and neuromelanin and oxidative damage in the nigrostriatal system.
    Kim ST; Choi JH; Chang JW; Kim SW; Hwang O
    J Neurochem; 2005 Oct; 95(1):89-98. PubMed ID: 16181415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic neurons.
    Chinta SJ; Andersen JK
    Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias).
    Barbeau A
    Neurotoxicology; 1984; 5(1):13-35. PubMed ID: 6538948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.